Cycle-length evidence
Teduglutide cycle length: what human studies ran
FDA-approvedAHuman trial evidence
Short answer: Teduglutide has no "cycle". As an approved drug it is used as its label and a prescriber direct.
Treatment and follow-up in human studies
No human study durations are recorded.
What has not been tested
- On-and-off schedules or breaks between courses.
- Repeated courses and long-term exposure beyond the periods listed.
- Teduglutide combined with other compounds, unless a study above says so.
Frequently asked questions
Is there an established Teduglutide cycle length?
No cycle is defined. Teduglutide is an approved drug whose label describes treatment under a prescriber's care; the label, not a cycle, governs duration.
What is the longest human study of Teduglutide?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
References
- GATTEX (teduglutide) for injection, prescribing information (DailyMed SPL version 20, published Sep 18, 2025) FDA label (DailyMed). 2025
- Drugs@FDA application NDA 203441 (GATTEX KIT, Takeda; original approval 2012-12-21) via openFDA FDA (openFDA Drugs@FDA). 2026
- Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure Gastroenterology. 2012
- Tractatenblad 2026 Nr. 25: Anti-doping convention (ETS No. 135), amendment to the appendix - The 2026 Prohibited List, World Anti-Doping Code (English text; entry into force 1 January 2026) Tractatenblad van het Koninkrijk der Nederlanden (official government publication). 2026
- PubChem compound record for teduglutide (CID 16139605) PubChem. 2026